NEW YORK (GenomeWeb) – Quark Pharmaceuticals this week presented data from a Phase II trial of QPI-1002, an siRNA-based drug for the prevention of delayed graft function (DGF) in kidney transplant patients. While the study's primary endpoint was not reached, patient outcomes were favorable enough that the company is now planning a Phase III trial that could begin as soon as early next year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: biobank of colorectal cancer organoids, ancient wolf genome analysis, and more.

With cloud computing becoming more attractive to researchers, Nature News offers some tips on how to get going.

In a series of articles, medical journals debate the necessity of conflict-of-interest policies.

Irwin Rose, who won the 2004 Nobel Prize in Chemistry for his work on ubiquitin-mediated protein degradation, has died.